Skip to main content

Table 2 Parameters comparisons with different doses of fenofibrate therapy

From: Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

Variables

CONT

UT

LFF

HFF

TG (mmol/L)

0.95 ± 0.06*

2.30 ± 0.40

2.18 ± 0.35

1.96 ± 0.24#

TC (mmol/L)

3.27 ± 0.25

3.31 ± 0.36

3.30 ± 0.24

3.28 ± 0.16

LDL-C (mmol/L)

1.99 ± 0.13

2.04 ± 0.16

2.01 ± 0.24

2.00 ± 0.21

HDL-C (mmol/L)

1.06 ± 0.04

0.90 ± 0.04

0.97 ± 0.05

1.03 ± 0.03#

ApoA1 (mmol/L)

1.03 ± 0.03

0.86 ± 0.04

0.92 ± 0.02

0.99 ± 0.05#

ApoB (mmol/L)

0.96 ± 0.05

0.98 ± 0.03

0.98 ± 0.04

0.98 ± 0.02

ALT (U/L)

27.5 ± 2.9

30.2 ± 1.6

29.0 ± 2.2

28.2 ± 1.5

AST (U/L)

28.4 ± 2.3

31.0 ± 2.5

29.5 ± 2.4

28.6 ± 1.0

FBG (mmol/L)

5.88 ± 0.15

6.04 ± 0.14

6.00 ± 0.13

6.00 ± 0.10

CRP (mg/L)

1.80 ± 0.13*

9.20 ± 1.04

9.09 ± 0.98

8.92 ± 0.76#

MDA(nmol/L)

0.98 ± 0.11*

3.35 ± 0.13

3.21 ± 0.16

3.03 ± 0.12#

NO(μmol/L)

13.21 ± 1.03*

9.16 ± 1.12

9.35 ± 1.08

9.98 ± 1.00#

ADMA (nmol/L)

68.24 ± 9.13*

97.33 ± 10.72

95.46 ± 10.33

91.25 ± 11.25#

  1. Denote: *P < 0.05 versus other groups, #P < 0.05 versus the CONT group.